|
|
1-Dodecylhexahydro-2H-azepin-2-one |
059277-89-3 |
C18H35NO |
|
|
(E)-N-[2-[4-[(3-Cyclohexyl-2-imino-1-imidazolidinyl)sulfonyl]phenyl]ethyl]-2-butenamide; trans-1-[[p-[2-(Crotonylamino)ethyl]phenyl]sulfonyl]-3-cyclohexyl-2-iminoimidazolidine |
085390-06-3 |
C21H30N4O3S |
|
|
4-Deoxy-4′-methylpyrido[1′,2′-1,2]imidazo[5,4-c]rifamycin SV |
080621-81-4 |
C43H51N3O11 |
|
|
1-(3-Dimethylaminopropyl)-1-(p-fluorophenyl)-5-phthalancarbonitrile monohydrobromide; 1-(3-Dimethylaminopropyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile monohydrobromide |
059729-32-7; 059729-33-8 (free base) |
C20H21FN2O.BrH |
|
|
(?)-cis-2,6-Dimethyl-alpha-phenyl-alpha-(2-pyridyl)-1-piperidinebutanol monohydrochloride; (?)-1-Phenyl-1-(2-pyridyl)-4-(cis-2,6-dimethyl-1-piperidyl)butanol monohydrochloride; (?)-cis-alpha-[3-(2,6-Dimethyl-1-piperidinyl)propyl]-alpha-phenyl-2-pyridine |
061477-94-9; 068252-19-7 (free base) |
C22H30N2O.ClH |
|
|
3-(1,3-Dihydro-3-oxo-2H-indol-2-ylidene)-1,3-dihydro-2H-indol-2-one |
000479-41-4 |
C16H10N2O2 |
 |
N-(1-Methyl-2-pyrrolidinylidene)-N’-phenyl-4-morpholinecarboxamidine; N-(1-Methyl-2-pyrrolidinylidene)-N’-phenyl-4-morpholinecarboximidamide |
075358-37-1; 078782-47-5 (fumarate) |
C16H22N4O |
 |
4-(4-Chlorophenyl)-5-[2-(4-phenyl-1-piperazinyl)ethyl]-1,3-dioxol-2-one; 4-(p-Chlorophenyl)-5-beta-(N’-phenyl)piperazinoethyl-1,3-dioxol-2-one |
071923-34-7; 071923-01-8 (diHCl) |
C21H21ClN2O3 |
|
|
6-Methoxy-4-[3-[(3R,4R)-3-vinyl-4-piperidyl]propyl]quinoline; 4-(R)-[3-(6-Methoxy-4-quinolyl)propyl]-3(R)-vinylpiperidine; (3R-cis)-4-[3-(3-Ethenyl-4-piperidinyl)propyl]-6-methoxyquinoline |
065843-79-0 (diHCl); 072714-74-0 (free base) |
C20H26N2O.ClH |
|
|
(+)-2,3,4,5-Tetrahydro-7,8-dimethoxy-3-methyl-1-phenyl-1H-3-benzazepine |
056030-50-3; 039624-66-3 (maleate) |
C19H23NO2 |
